奥贝胆酸治疗原发性胆汁性胆管炎的真实世界肝脏结局(HEROES):一项试验模拟研究设计
本研究采用试验模拟设计,利用Komodo医疗索赔数据库链接美国国家实验室、移植和死亡数据库,比较接受奥贝胆酸(OCA)治疗与未接受OCA治疗的原发性胆汁性胆管炎患者。主要终点为死亡、肝移植或肝失代偿住院的首次发生时间。OCA组8例事件,加权对照组32例事件(HR=0.37;95%CI=0.14-0.75;p<0.001)。结论为OCA治疗者较未治疗者上述复合终点风险降低63%。
要点
- OCA组8例事件,加权对照组32例事件(HR=0.37;95%CI=0.14-0.75;p<0.001)。
- OCA组中位随访9.3(95%CI 8.4-10.6)个月,非OCA组17.5(95%CI 16.2-18.6)个月(加权人群;停药时删失)。
- 复合终点各组成部分效应一致。
核心结论
- OCA治疗者较未治疗者死亡、肝移植或肝失代偿住院的复合终点风险降低63%。
研究设计与样本
- 试验模拟研究,使用Komodo医疗索赔数据库链接美国国家实验室、移植和死亡数据库。
- 纳入代偿期原发性胆汁性胆管炎且对熊去氧胆酸不耐受或应答不佳的患者,比较启动OCA治疗者与符合OCA条件但未治疗者。
- 主要分析中,4174例患者贡献11246个对照索引日期,403例患者贡献OCA索引日期。
- 采用倾向评分加权Cox比例风险模型,标准化发病比加权平衡基线预后因素。
主要发现
- OCA组发生8例事件,加权对照组发生32例事件(HR=0.37;95%CI=0.14-0.75;p<0.001)。
- OCA组中位随访9.3(95%CI 8.4-10.6)个月,非OCA组17.5(95%CI 16.2-18.6)个月(加权人群;停药时删失)。
- 复合终点各组成部分效应一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Primary biliary cholangitis is a rare, progressive liver disease. Obeticholic acid (OCA) received accelerated approval for treating patients with primary biliary cholangitis in whom ursodeoxycholic acid failed, based on a surrogate endpoint of reduction in ALP. Analysis of the long-term safety extension with 2 external control groups demonstrated a significant increase in event-free survival in OCA-treated patients. This fully real-world evidence study assessed the effect of OCA treatment on clinical outcomes. APPROACH AND RESULTS: This trial emulation used data from the Komodo Healthcare Map claims database linked to US national laboratory, transplant, and death databases. Patients with compensated primary biliary cholangitis and intolerance/inadequate response to ursodeoxycholic acid who initiated OCA therapy were compared with patients who were OCA-eligible but not OCA-treated. The primary endpoint was time to the first occurrence of death, liver transplant, or hospitalization for hepatic decompensation, analyzed using a propensity-score weighted Cox proportional hazards model. Baseline prognostic factors were balanced using standardized morbidity ratio weighting. For the primary analysis, 4174 patients contributed 11,246 control index dates, and 403 patients contributed OCA indexes. Weighted groups were well balanced. Median (95% CI) follow-up in the OCA and non-OCA arms was 9.3 (8.4-10.6) months and 17.5 (16.2-18.6) months (weighted population; censored at discontinuation). Eight events occurred in the OCA arm and 32 in the weighted control (HR = 0.37; 95% CI = 0.14-0.75; p < 0.001). Effects were consistent for each component of the composite endpoint. CONCLUSIONS: We identified a 63% reduced risk of hospitalization for hepatic decompensation, liver transplant, or death in OCA-treated versus non-OCA-treated individuals. TRIAL REGISTRATION: HEROES; ClinicalTrials.gov NCT05292872.
引用
- Brookhart MA, Mayne TJ, Coombs C, et al. Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design. Hepatology. 2025. PMID: 39630028. doi:10.1097/HEP.0000000000001174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。